The Fund aims to provide long term capital and income growth by investing predominantly in the UK. The Fund will invest predominantly in UK equities, fixed interest and other securities. The Authorised Corporate Director may also invest at its discretion in other transferable securities, money market instruments, deposits, cash and near cash and collective investment schemes.
Name | % Net Assets |
---|---|
GlaxoSmithKline | 4.6% |
Standard Life Investments UK Equity Unconstrained Class I | 4.5% |
Royal Dutch Shell B | 4.3% |
BP | 4.2% |
Vodafone Group | 4.2% |
British American Tobacco | 3.4% |
Aberforth UK Small Companies | 3.2% |
HSBC Holdings PLC (UK Reg) | 2.9% |
BG Group | 2.3% |
AstraZeneca | 2.3% |
Key | % Net Assets |
---|---|
GlaxoSmithKline | 4.6% |
Standard Life Investments UK Equity Unconstrained Class I | 4.5% |
Royal Dutch Shell B | 4.3% |
BP | 4.2% |
Other | 82.4% |
Date | n/a |
---|---|
Bid | 0.00 |
Offer | 0.00 |
Currency | n/a |
Change | 0.00 |
% | n/a |
YTD change | 0.00 |
YTD % | n/a |
Fund Inception | 31/07/1998 |
---|---|
Fund Manager | n/a |
TER | - |
Minimum Investment | |
---|---|
Initial | n/a |
Additional | n/a |
Savings | n/a |
Charges | |
---|---|
Initial | n/a |
Annual Mang't | 1.50% |
Exit | n/a |
Name | % |
---|---|
No risk data available. |
You are here: research